On April 7, 2025, Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND trial for setmelanotide, showing a significant reduction in BMI among patients with acquired hypothalamic obesity, with a 19.8% placebo-adjusted difference and 80% of patients achieving at least a 5% BMI reduction; the company also stated it has enough funds to operate into 2027.